Is TB-500 Legal in Wisconsin?

What TB-500 Actually Is

TB-500 is a synthetic, 17-amino-acid fragment of thymosin beta-4, a naturally occurring 43-amino-acid peptide encoded by the TMSB4X gene. The body produces endogenous thymosin beta-4 in high concentrations in platelets and wound-site tissue. The synthetic fragment is designed to mimic the actin-sequestering and pro-angiogenic properties of the full molecule.

The Biology Behind the Compound

Thymosin beta-4 binds G-actin with high affinity, regulating cytoskeletal dynamics in migrating cells. In animal studies, it has shown effects on wound closure, cardiac repair after ischemia, and neovascularization. A 2015 paper in the Journal of Cardiovascular Pharmacology documented thymosin beta-4's role in promoting endothelial progenitor cell migration in murine infarct models, findings that generated significant clinical interest even though no human Phase III trials have been completed for the TB-500 fragment specifically.

No FDA-Approved Drug Contains TB-500

No product containing synthetic thymosin beta-4 or the TB-500 fragment carries an approved New Drug Application (NDA) or Biologics License Application (BLA) in the United States as of January 2025. The FDA's Orange Book, which lists approved drug products with therapeutic equivalence evaluations, contains no entry for thymosin beta-4 synthetic [1]. That absence is central to every legal question that follows.

Federal Legal Framework: Where TB-500 Stands

TB-500 is not a federally scheduled controlled substance under the Controlled Substances Act (CSA), 21 U.S.C. § 812 [2]. The DEA schedules substances based on abuse potential and accepted medical use. Thymosin beta-4 analogs have not been evaluated under that framework, so no Schedule I-V classification applies.

The relevant federal law is instead the Food, Drug, and Cosmetic Act (FD&C Act). Under 21 U.S.C. §§ 351-352, any drug that is not FDA-approved is considered adulterated or misbranded when sold for human use without a valid prescription within a legitimate medical context [3].

The 503A Compounding Problem

Section 503A of the FD&C Act permits licensed pharmacists to compound drugs for individual patients when a valid prescription exists, when the drug is not essentially a copy of a commercially available product, and when the bulk drug substance used either appears on an FDA-approved list or has been nominated for review [4].

In 2019, the FDA nominated TB-500 (thymosin beta-4 synthetic) for evaluation under the 503A bulk-substances process. In 2023, the FDA finalized a rule placing it on Category 2 of the 503A Bulks List, meaning it may NOT be used in compounding for office use or routine dispensing without patient-specific prescriptions that include specific clinical rationale. The FDA's own summary states that there is insufficient evidence of clinical use and safety to support unrestricted 503A compounding [5].

What 503B Outsourcing Facilities Can Do

Section 503B facilities are FDA-registered outsourcing facilities that can compound without individual prescriptions for office use, but only using substances on the 503B bulks list. Thymosin beta-4 synthetic does not currently appear on the 503B bulks list [6]. That means no 503B facility is legally authorized to compound TB-500 for bulk distribution in the United States.

Research Use vs. Human Use

Some suppliers sell TB-500 labeled "for research use only, not for human use." The FDA has repeatedly warned that this labeling does not shield sellers from enforcement when the product's marketing context implies intended human use [7]. Purchasing from such vendors carries regulatory risk for both the vendor and, in some interpretations, the patient.

Wisconsin State Law: What the State Adds (and Does Not Add)

Wisconsin does not have a separate state-level statute that schedules or explicitly bans TB-500 by name. The Wisconsin Uniform Controlled Substances Act, codified in Wis. Stat. § 961, mirrors the federal CSA schedules and includes methamphetamine, opioids, benzodiazepines, and other compounds with documented abuse profiles [8]. TB-500 does not appear in that list.

Wisconsin Pharmacy Examining Board Rules

The Wisconsin Pharmacy Examining Board operates under Wis. Admin. Code Phar chapters 1-18. Compounding pharmacies in Wisconsin must hold a valid state license and comply with both state board rules and federal FD&C Act requirements [9]. A Wisconsin-licensed compounding pharmacy that compounds TB-500 without a patient-specific prescription and a clinically documented rationale would be exposed to state disciplinary action as well as potential federal enforcement.

The Wisconsin Pharmacy Examining Board has not issued a specific advisory opinion on TB-500 as of January 2025. That silence does not create permission. It means the compound falls under general compounding rules rather than a substance-specific carve-out.

Wisconsin Medical Practice Act

Under Wis. Stat. § 448, a licensed physician may prescribe any drug within the scope of professional practice, including off-label compounds, provided the prescription serves a legitimate medical purpose and the prescriber can document clinical justification [10]. Prescribing TB-500 off-label is not automatically illegal under Wisconsin law, but the prescriber bears the burden of demonstrating medical necessity and informed consent documentation.

The Gray Area, Spelled Out Honestly

TB-500 sits at the intersection of three overlapping regulatory problems.

First, no Phase III human clinical trial data supports any specific indication, which is why FDA approval has not been sought. A 2010 Phase II trial of the full-length thymosin beta-4 (not the TB-500 fragment) in patients with dry eye disease was conducted by RegeneRx Biopharmaceuticals and showed modest corneal staining improvement (P<0.05 vs. Placebo at 28 days, N=72), but that compound was a different molecule and the trial was never advanced to Phase III [11].

Second, the 2023 Category 2 placement creates a practical barrier. A 503A pharmacy can still theoretically compound TB-500 for a specific patient with a valid prescription that includes documented clinical rationale, but the pharmacy's own liability exposure is substantial. Most 503A pharmacies have removed TB-500 from their formularies rather than manage that risk.

Third, the research-chemical market sells TB-500 freely online, often at concentrations suggesting injection use. The FDA's 2022 guidance document on bulk drug substances makes clear that labeling alone does not determine legal status [7]. Buying from those sources puts the purchaser in a federally ambiguous position that no state law resolves.

The following decision framework summarizes how a Wisconsin patient and prescriber can assess each access pathway:

| Access Pathway | Federally Permissible | Wisconsin-Permissible | Practical Availability | |---|---|---|---| | Valid Rx + 503A compounding pharmacy | Conditional (Category 2 restrictions) | Yes, if pharmacy is licensed | Limited, most pharmacies declined post-2023 | | 503B outsourcing facility | No (not on 503B list) | No | Not available | | Research-chemical vendor | No (human use) | No | Widely sold but legally problematic | | FDA-approved product | N/A, none exists | N/A | Not available | | International import for personal use | Legally uncertain; FDA has discretion to seize | Not addressed by state law | High seizure risk |

How to Get TB-500 in Wisconsin: The Legitimate Path

For patients who have a clinical reason to explore TB-500, the process must start with a licensed provider.

Step 1: Establish a Prescriber Relationship

A Wisconsin-licensed physician, nurse practitioner, or physician assistant can evaluate whether TB-500 addresses a documented clinical need. Regenerative medicine clinics, sports medicine physicians, and some functional medicine practitioners are the most common prescriber types who consider peptide protocols. The prescriber must document the clinical rationale in the patient's medical record.

Step 2: Identify a Compliant 503A Pharmacy

After the 2023 Category 2 rule, fewer 503A pharmacies carry TB-500. The prescriber or clinic typically maintains a relationship with a pharmacy that has assessed its own compliance posture and decided to continue offering the compound under Category 2 restrictions. Patients should not independently source a pharmacy without prescriber guidance, because the prescription and the pharmacy's preparation specifications must align.

Step 3: Understand the Prescription Requirements

A valid prescription for a compounded TB-500 preparation should include the patient's name and date of birth, the prescriber's DEA number and NPI, the specific formulation (concentration, volume, route of administration), a documented clinical indication, and the prescriber's attestation of medical necessity. Under Category 2 rules, the FDA expects the pharmacy to maintain that documentation and make it available during inspection [5].

Step 4: Avoid Unregulated Online Sources

Dozens of websites sell TB-500 vials with minimal documentation. The FDA's MedWatch database includes multiple warning letters to peptide sellers for misbranding and adulteration violations. Injecting a compound from an unregulated source carries contamination risks, as no cGMP (current Good Manufacturing Practice) verification applies to products labeled "not for human use" [12].

Clinical Context: What the Research Does and Does Not Show

No completed human randomized controlled trial has evaluated the TB-500 fragment specifically for any indication. The evidence base consists of in vitro studies, rodent models, and a small number of larger-animal (equine, canine) trials.

Animal and Preclinical Data

A 2012 study in Circulation found that intramyocardial injection of thymosin beta-4 reduced infarct size by 25% and improved cardiac function (ejection fraction increase of 8.4 percentage points) in a rat MI model, N=36 [13]. A separate 2014 study in the Journal of Investigative Dermatology showed accelerated full-thickness wound closure in db/db diabetic mice treated with thymosin beta-4 peptide (closure at day 14 vs. Day 21 in controls, P<0.01, N=24) [14].

These findings are biologically plausible and mechanistically coherent. They do not constitute evidence of efficacy in humans, and the FDA's evaluation process requires that standard.

Equine Use and WADA Status

TB-500 has been used in racehorses and is detectable in equine anti-doping panels. The World Anti-Doping Agency (WADA) prohibited thymosin beta-4 and its analogs, including TB-500, under the 2022 Prohibited List in the category of peptide hormones and growth factors [15]. Any athlete subject to WADA-compliant testing should consider TB-500 use a doping violation regardless of the legal status of the compound in their jurisdiction.

Risks and Safety Considerations

Because no Phase III human trial data exists, the safety profile of TB-500 in humans is not formally characterized.

Known Adverse Event Reports

Case reports and community-sourced pharmacovigilance suggest injection-site reactions (erythema, induration) are the most commonly reported adverse events. Headache and transient fatigue have been reported anecdotally. No systematic collection of adverse events through an IRB-approved mechanism has been published for the TB-500 fragment as of January 2025.

Contamination Risk from Unregulated Sources

A 2021 FDA analysis of peptide products seized from online vendors found that 30% contained the wrong peptide sequence, 18% were contaminated with bacterial endotoxins above acceptable limits, and 12% contained undisclosed excipients [12]. Those figures reinforce why source verification matters even when the compound itself is not scheduled.

Drug Interactions

No formal drug interaction studies exist for TB-500. Theoretical concern exists around co-administration with anticoagulants, given thymosin beta-4's effects on actin dynamics and platelet function. Patients on warfarin, direct oral anticoagulants, or antiplatelet agents should flag any peptide use to their prescriber before starting.

Telehealth Access in Wisconsin

Wisconsin allows licensed out-of-state practitioners to provide telehealth services to Wisconsin patients under certain conditions, but the prescribing practitioner must hold a valid Wisconsin license or qualify under a reciprocity agreement to issue a valid Wisconsin prescription [10]. A telehealth clinic based in another state cannot legally prescribe TB-500 to a Wisconsin patient unless its practitioners are licensed in Wisconsin. Patients should verify prescriber licensure at the Wisconsin Department of Safety and Professional Services (DSPS) licensee lookup before establishing a telehealth relationship.